A Phase 2 Randomized Open-label, Dose-ranging Study for Ureter Visualization Using ASP5354 in Subjects Undergoing Laparoscopic/Minimally Invasive Colorectal Surgery
Latest Information Update: 13 May 2024
Price :
$35 *
At a glance
- Drugs Pudexacianinium (Primary)
- Indications Unspecified
- Focus Diagnostic use
- Sponsors Astellas Pharma
- 01 May 2024 Results assessing appropriate doses of pudexacianinium for this study, published in the Clinical Pharmacology in Drug Development.
- 19 Dec 2021 Status changed from recruiting to completed.
- 15 Jul 2021 Planned End Date changed from 30 Jun 2021 to 30 Nov 2021.